{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:55:16Z","timestamp":1759366516422,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.revmed.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:25:52Z","timestamp":1695889552000},"page":"533-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoglobulines intraveineuses et dermatomyosites\u00a0: le New England Journal of Medicine qui change la donne\u00a0?"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-1181","authenticated-orcid":false,"given":"S.","family":"Mensi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8558","authenticated-orcid":false,"given":"A.","family":"Lescoat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.revmed.2023.09.002_bib0105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.revmed.2023.09.002_bib0110","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"10.1016\/j.revmed.2023.09.002_bib0115","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.revmed.2023.09.002_bib0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316\u00a0December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.revmed.2023.09.002_bib0125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.revmed.2023.09.002_bib0130","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.revmed.2023.09.002_bib0135","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.revmed.2023.09.002_bib0140","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.revmed.2023.09.002_bib0145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.revmed.2023.09.002_bib0150","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2\u00a0or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2023.09.002_bib0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","article-title":"Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota","volume":"146","author":"Bendewald","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.revmed.2023.09.002_bib0160","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"4","key":"10.1016\/j.revmed.2023.09.002_bib0165","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2022.10.055","article-title":"JAK inhibitors for the treatment of adult dermatomyositis: a pilot study","volume":"88","author":"Landon-Cardinal","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.revmed.2023.09.002_bib0170","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5\u00a0antibody","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.revmed.2023.09.002_bib0175","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.09.002_bib0180","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2023.09.002_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00005-016-0410-1","article-title":"Anaphylaxis to IVIG","volume":"65","author":"Williams","year":"2017","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"10.1016\/j.revmed.2023.09.002_bib0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2023.09.002_bib0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.revmed.2013.07.006","article-title":"Traitements par immunoglobulines et complications thrombotiques","volume":"35","author":"Darnige","year":"2014","journal-title":"Rev Med Interne"},{"issue":"9","key":"10.1016\/j.revmed.2023.09.002_bib0100","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/11592740-000000000-00000","article-title":"Special considerations with the use of intravenous immunoglobulin in older persons","volume":"28","author":"Cheng","year":"2011","journal-title":"Drugs Aging"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323007282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323007282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:46:51Z","timestamp":1759337211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866323007282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0248866323007282"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.09.002","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulines intraveineuses et dermatomyosites\u00a0: le New England Journal of Medicine qui change la donne\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}